Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy

Affiliations

¹ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France. Electronic address: amaury.daste@chu-bordeaux.fr.
² Department of Otolaryngology - Head and Neck Surgery, Pellegrin Hospital, University Hospital, CHU Bordeaux, France.
³ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France; Department of Otolaryngology - Head and Neck Surgery, Pellegrin Hospital, University Hospital, CHU Bordeaux, France.
⁴ Department of Radiation Therapy, Haut Leveque Hospital, University Hospital, CHU, Bordeaux, France.
⁵ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France.
⁶ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France; University of Bordeaux, Bordeaux, France.
⁷ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France; University of Bordeaux, Bordeaux, France; ImmunoConcEpt, CNRS UMR 5164, Bordeaux University, Bordeaux 33076, France.

Amaury Daste et al. Oral Oncol. 2018 Jun.

. 2018 Jun:81:116-118.

doi: 10.1016/j.oraloncology.2018.04.013. Epub 2018 Apr 24.

¹ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France. Electronic address: amaury.daste@chu-bordeaux.fr.
² Department of Otolaryngology - Head and Neck Surgery, Pellegrin Hospital, University Hospital, CHU Bordeaux, France.
³ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France; Department of Otolaryngology - Head and Neck Surgery, Pellegrin Hospital, University Hospital, CHU Bordeaux, France.
⁴ Department of Radiation Therapy, Haut Leveque Hospital, University Hospital, CHU, Bordeaux, France.
⁵ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France.
⁶ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France; University of Bordeaux, Bordeaux, France.
⁷ Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France; University of Bordeaux, Bordeaux, France; ImmunoConcEpt, CNRS UMR 5164, Bordeaux University, Bordeaux 33076, France.

No abstract available

Keywords: Check point inhibitors; Head and neck cancer; Pseudo-progression.

Publication types